צמיחת הכנסות שנתית ב-12 החודשים האחרונים: Assembly Biosciences (ASMB)

Assembly Biosciences aims to capture the global hepatitis B therapy market through the development of unique patents. Revenue volatility compared to the same period last year for the TTM reflects sales dynamics, where the value of 79.90 represents the latest figure. Current cash flow remains volatile prior to product commercialization, while operational flexibility is maintained by outsourcing drug synthesis to certified external laboratories.

Investors utilize this indicator as a leading signal of market expansion to assess business scaling rates. The metric measures the percentage deviation of current twelve-month revenue from the same period last year, which, in terms of rolling year-over-year relative revenue change, reflects the efficiency of Assembly Biosciences (ASMB) diversified hubs in supporting clinical trials.